Evaluation of Safety and Efficacy of Albuterol with and without Preservatives
Project Description: In October 2015, the UF Health P&T Committee voted to approve the addition of BAC-containing albuterol solution to the Formulary with the provision that a three-month analysis of adverse events be performed. A single-center retrospective review of all patients receiving continuous albuterol for nebulization between July 27, 2015 and January 26, 2016 will be conducted. Patients will be divided into two cohorts based upon date of albuterol initiation prior to or after the change to a BAC-containing albuterol product occurred on October 27, 2015. Patients intubated for the full duration of albuterol therapy will be excluded from analysis. Evaluated endpoints will include duration of continuous albuterol nebulization therapy, duration of supplemental oxygen requirement, and documentation of poor patient response by physicians or respiratory therapists within the electronic medical record. Poor response will be defined as need for escalation in oxygen support, escalation in albuterol dose requirements after one hour, addition of alternative therapy, or occurrence adverse drug event. Mean total and weight-based hourly dosage requirements will also be calculated, and presence of confirmed viral or bacterial infection will be evaluated.
QPI: Lucas, Orth, (email@example.com)
Collaborators: Shelley, Collins, (firstname.lastname@example.org); Carrie, Lagasse, (email@example.com); Matthew, Ryan, (firstname.lastname@example.org); Brian, Kelly, (email@example.com)
Advisors: Carrie, Lagasse, (firstname.lastname@example.org)
UF Health Big Aims: Zero Harm None
MeSH Keywords: Albuterol, Asthma, Benzalkonium Compounds, Status Asthmaticus, Bronchoconstriction